Thursday, Sep 20, 2018
engineered enzymes for better healthcare

 

Galactosaemia (GAL) results from a deficiency in the enzyme needed to metabolise galactose (a component of milk sugar) and occurs in about 1 in every 40,000 newborns. The incidence in the Irish travellers’ community is 1 in every 450. Newborns with GAL typically appear normal. However within a few days after initiating milk feeding, vomiting, lethargy, diarrhoea, jaundice and liver damage develops. The disorder may result in developmental retardation, growth failure, cataracts and in severe cases death. With early detection and strict galactose-free diet, infants diagnosed with GAL can achieve satisfactory general health.

Product Info

 

amino acid disorders productEnzyme Deficiency Disorders

GAL      Galactosaemia

G6PD    Glucose-6P Dehydrogenase Deficiency

BIO       Biotinidase Deficiency

 

Language Selection

Search

Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…

Read more...

Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…

Read more...

UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…

Read more...